Cannabis and Cannabinoid Research Publishes Data Demonstrating the Degradation of Cannabidiol to Psychoactive Cannabinoids when Exposed to Simulated Gastric Fluid

Transdermal CBD Gel ZYN002 has the potential to avoid bioconversion to psychoactive THC by bypassing the gastrointestinal tract

DEVON, Pa., April 12, 2016 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), a specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today announced the publication of important in vitro data demonstrating that the acidic pH conditions provided by simulated gastric fluid (SGF) converts cannabidiol (CBD) into the psychoactive components Δ9- tetrahydrocannabinol (THC), Δ8-THC and other psychoactive cannabinoids. The paper, titled “Identification of Psychoactive Degradants of Cannabidiol in Simulated Gastric and Physiological Fluid,” was published online in Cannabis and Cannabinoid Research on April 9, 2016. The full publication can be accessed here.

Click here to read the full press release.

©2020 PACT All Rights Reserved